


## Letters of intent

Increase access, improve consistency and reduce duplication

Since the pCPA's inception, **621** negotiations have reached a letter of intent (LOI), including:

- **225** for oncology
- **61** for biosimilars
- **69** for expensive drugs for rare diseases (EDRD)




## Savings

Lower drug costs


As of **April 1, 2024** savings from pCPA activities to participating drug plans are estimated to be **\$4.63B** annually.

- **\$3.72B** from brand name drugs
- **\$914M** from generic drugs
- Cumulative savings are estimated to be **\$24.0B**




## HTA and pCPA volumes

- 2024 will have **15 to 20 more HTA** recommendations than the average of recent years.
- The pCPA has **increased its capacity** to start new negotiations since the beginning of the year to respond to increased HTA volumes.




## pCPA activity

- The pCPA has consistently had **20 files or more** in consideration for negotiations from 2021 onwards.
- The queue increased in Q2 2024 but has decreased in **Q3 2024**.
- The pCPA averaged 35 files in active negotiation in 2021 and 2022, but **levels decreased in early 2024**.
- This was followed by an **increase in active files through mid-2024**.



## pCPA timelines

- Median engagement and total timelines have **improved from 2020 to 2024**, but only a minority of files meet the targets outlined in the brand process guidelines.
- Active negotiation timelines continue to decrease over time, with **2024 projected to be a record year** for the pCPA.



\* Time under consideration and total timelines are only assessed for files arising from HTA recommendations, and excludes files that do not undergo negotiations. pCPA targets outlined in the brand process guidelines are approximately two months for file engagement, four months for active negotiations and six months combined.